Andere Sprachen Carisma Therapeutics, Inc.

Aktien

A3DZG2

US14216R1014

CARM

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:14:57 02.05.2024			% 5 Tage	% 1. Jan.
1,56 ^USD	-4,29 %		-3,35 %	-45,90 %

13:30	Carisma Therapeutics ernennt Dr. Eugene P. Kennedy zum Chief Medical Officer	CI
11.04.	CARISMA THERAPEUTICS, INC. : Kaufen-Bewertung von BTIG	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Carisma Therapeutics : Corporate Presentation May 2024	15:04
Carisma Therapeutics : Corporate Presentation May 2024	15:03
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer	13:31
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer	13:30
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy Annual Meeting	23.04.
Carisma Therapeutics to Present at Upcoming Conferences	03.04.
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	02.04.
Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline	01.04.
Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01.04.
Carisma Therapeutics Announces Changes to its Board of Directors	01.04.
Carisma Therapeutics, Inc. Announces Changes to Its Board of Directors	01.04.
North American Morning Briefing : Stock Futures -2-	19.03.
North American Morning Briefing : Inflation Data -2-	12.03.
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference	28.02.
Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	21.12.
Carisma Therapeutics' First Lead Candidate Under Moderna Deal to Target Cancer Treatment	14.12.
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy	28.11.
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte	28.11.
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte	28.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Carisma Therapeutics, Inc.

Aktien

A3DZG2

US14216R1014

CARM

Andere Sprachen

Filter